Finjozy Tablet
Product Images NDC 58657-275

8 FDA label images from Method Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Finjozy (NDC 58657-275). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Method Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (Table 1)

1 (Table 1)
A table titled 'Recommended Daily Dosage of FINJOZY in Patients with MDD, OCD, PD, PTSD, and SAD' listing starting doses and therapeutic ranges. It divides dosage recommendations for adults (MDD 50 mg, OCD 50 mg, PD/PTSD/SAD 25 mg) and pediatric patients with OCD by age group (6-12 years 25 mg, 13-17 years 50 mg), with a therapeutic range of 50-200 mg for applicable indications.*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
A data table showing risk differences in suicidal thoughts or behaviors per 1000 patients treated in placebo-controlled trials of antidepressants by age group. It presents increases compared to placebo in patients under 18 and ages 18-24, and decreases compared to placebo in patients aged 25-64 and 65 or older.*
FDA Label Image

Table 3.1 (Table 3 1)

Table 3.1 (Table 3 1)
A table comparing common adverse reactions from pooled placebo-controlled trials involving FINJOZY and placebo in adults with various psychiatric disorders. It lists reaction categories such as cardiac, eye, gastrointestinal, general disorders, metabolism, and nervous system disorders, showing percentages for each reaction in both the FINJOZY and placebo groups.*
FDA Label Image

Table 3.2 (Table 3 2)

Table 3.2 (Table 3 2)
A data table presenting adverse reactions experienced by patients using FINJOZY 75 mg tablets. It categorizes reactions under Psychiatric Disorders, Reproductive system and breast disorders, and Skin and subcutaneous tissue disorders, listing specific symptoms such as insomnia, agitation, decreased libido, ejaculation issues, and hyperhidrosis with corresponding percentage occurrences in treatment and placebo groups.*
FDA Label Image

Table 4 (Table 4)

Table 4 (Table 4)
A data table presenting the most common sexual adverse reactions (≥2% and twice placebo) in men and women treated with FINJOZY compared to placebo. The table lists percentages for conditions such as ejaculation failure, decreased libido, erectile dysfunction, ejaculation disorder, and male sexual dysfunction in men, and decreased libido in women, showing higher rates in the FINJOZY groups versus placebo.*
FDA Label Image

Table 5 (Table 5)

Table 5 (Table 5)
A data table titled 'Clinically-Significant Drug Interactions with FINJOZY' listing various drug interaction categories including Monoamine Oxidase Inhibitors (MAOIs), Pimozide, other serotonergic drugs, drugs affecting hemostasis, drugs highly bound to plasma protein, drugs metabolized by CYP2D6, phenytoin, and drugs that prolong the QTc interval. The table presents clinical impacts, interventions, and examples for each category related to FINJOZY (sertraline hydrochloride) 75 mg oral tablets.*
FDA Label Image

Struct (Structure)

Struct (Structure)
Chemical structure of sertraline hydrochloride showing the detailed molecular arrangement including two chlorine atoms attached to a phenyl ring, a methylamino group, and a cyclohexane ring.*
FDA Label Image

Label-75mg (Label 75mg)

Label-75mg (Label 75mg)
FINJOZY 75 mg sertraline hydrochloride tablets label for oral use, containing 30 film-coated tablets. The label includes dispensing information, storage instructions, manufacturer Method Pharmaceuticals LLC, and distributor details for Ascent Pharmaceuticals. The NDC is 58657-275.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.